PRESS RELEASE published on 06/29/2023 at 07:30, 3 years 3 months ago Formycon announces submission of the biologics license application (BLA) for FYB203, an aflibercept biosimilar candidate to the U.S. Food and Drug Administration (FDA)
PRESS RELEASE published on 05/30/2023 at 07:30, 3 years 4 months ago Formycon reports results for the first quarter 2023
PRESS RELEASE published on 05/10/2023 at 07:30, 3 years 4 months ago Formycon Announces Participation in International Investor Conferences in Q2/2023
PRESS RELEASE published on 04/27/2023 at 07:30, 3 years 5 months ago Formycon publishes results for financial year 2022
PRESS RELEASE published on 04/25/2023 at 07:00, 3 years 5 months ago Formycon announces successful results of Phase I clinical trial for ustekinumab biosimilar candidate FYB202 and concludes clinical development
PRESS RELEASE published on 02/07/2023 at 07:30, 3 years 7 months ago Enno Spillner appointed Chief Financial Officer (CFO) of Formycon AG
PRESS RELEASE published on 02/06/2023 at 07:30, 3 years 7 months ago Aflibercept Biosimilar Candidate FYB203 shows comparable efficacy to the reference product Eylea®1 in Phase III Study
PRESS RELEASE published on 02/02/2023 at 08:00, 3 years 8 months ago Formycon and Fresenius Kabi conclude global commercialization partnership for FYB202, a biosimilar candidate to Stelara®1 (ustekinumab)
PRESS RELEASE published on 02/02/2023 at 07:30, 3 years 8 months ago EQS-Adhoc: Formycon AG announces result of private placement and sets placement price for the new shares from the capital increase
PRESS RELEASE published on 02/01/2023 at 23:30, 3 years 8 months ago EQS-Adhoc: Formycon AG upsizes capital increase from authorized capital following strong demand
Published on 10/05/2026 at 14:45, 5 hours 33 minutes ago NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
Published on 10/05/2026 at 14:30, 5 hours 48 minutes ago Hillcrest and Equipmake Expand Partnership Talks to Include Commercial Licensing of ZVS Technology
Published on 10/05/2026 at 14:30, 5 hours 48 minutes ago Solitario CEO to Present at John Tumazos Very Independent Research, LLC
Published on 10/05/2026 at 14:00, 6 hours 18 minutes ago Tectonic Metals Appoints Eduard Epshtein as CFO, Bolstering Executive Team for Next Stage of Growth
Published on 10/05/2026 at 14:00, 6 hours 18 minutes ago GameSquare to Present at Upcoming Investor Conferences
Published on 10/05/2026 at 19:30, 48 minutes ago EEII AG: Suspension of the Jubin Frères SA Reverse Takeover
Published on 10/05/2026 at 19:00, 1 hour 18 minutes ago PATRIMOINE ET COMMERCE: Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 28 septembre 2026 au 02 octobre 2026
Published on 10/05/2026 at 18:30, 1 hour 48 minutes ago init is entering the market for the management of autonomous fleets through a stake in successful Norwegian start-up
Published on 10/05/2026 at 18:13, 2 hours 5 minutes ago Disclosure of shares outstanding and voting rights - 05.10.2026
Published on 10/05/2026 at 18:13, 2 hours 5 minutes ago Déclaration nombre d'actions et droits de vote - 05.10.2026
Published on 10/05/2026 at 18:00, 2 hours 18 minutes ago LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 30 septembre 2026
Published on 10/05/2026 at 17:45, 2 hours 33 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 10/05/2026 at 17:45, 2 hours 33 minutes ago Declaration of voting rights at the end of September 2026
